Zoll Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software services, has acquired Respicardia Inc., a provider of novel implantable neurostimulators for the treatment of moderate to severe central sleep apnea.
“Zoll and Respicardia both develop innovative therapies for conditions with large unmet clinical needs, and we share a deep commitment to improving patient outcomes,” said Jon Rennert, CEO of Zoll. “With this acquisition, Zoll will combine its expertise in cardiac and respiratory care with Respicardia’s novel remedē system to make a meaningful difference in the health and quality of life for many patients.”
“Respicardia is excited to be joining the ZOLL family,” said Peter Sommerness, CEO of Respicardia. “As an innovator of safe and effective therapies that address the unmet needs of respiratory and cardiovascular patients, we see tremendous potential ahead with the support of ZOLL’s strong brand and global reach.”